24 September 2025   Berkeley-based Prellis Biologics, Inc. , developer of human in vitro antibody generation platform, announces collaboration with Eli Lilly to accelerate the discovery of human antibodies for multiple disease targets.   Prellis’ EXIS™ lymph node platform for target‑specific human antibody generation is a shining example of ingenuity by which several technologies were combined to capture human-relevant physiology.   The traditional method of antibody generat

09 December 2025   Riccardo Levato’s team at UMC Utrecht and Utrecht University receives  an ERC Consolidator Grant of approx. €2.3M to advance the next phase of its innovative method of 3D bioprinting.     The technique of 3D bioprinting of living tissues to recapitulate the structure and function of human organs has shown great promise in disease modelling, drug testing and regenerative medicine. Supported by a 2020 ERC Starting Grant, Riccardo Levato’s team developed a mod

12 November 2025   Inventia Life Science's 3D bioprinted patient-derived cancer models has opened the door for Hunter Medical Research Institute to advance its drug repurposing program into Australian New Zealand clinical trials .   The drug in question, efavirenz, is known as an antiretroviral NNRTI (non‑nucleoside reverse transcriptase inhibitor) used for treating HIV. Its repurposing has the potential to improve the survival of patients with high-grade serous ovarian cance